SERPINA1 and alpha 1-antitrypsin deficiency: Based on observational studies of AATD patients, a threshold serum level of 11 μM, or an ELF level of at least 1.2 μM (equal to 63 μg/ml) AAT has been postulated for clinically effective AAT substitution therapy to protect from emphysema formation.